Transcript US Emerging Pulmonary Drug Delivery

U.S. Emerging Pulmonary Drug
Delivery Technologies Markets
Technological Innovation to Drastically Change
Market Landscape
“The development of path breaking, non-invasive, pulmonary drug delivery
technologies such as chlorofluorocarbons (CFC)-free metered dose inhalers
(MDI), dry powder inhalers (DPI), and liquid-based inhalers (LBIs) invites
many companies to enter the lucrative market, intensifying competition.”
Pharmaceutical Biotech Analyst Team
Frost & Sullivan
© Copyright 2002 Frost & Sullivan. All Rights Reserved.
Key Features
Frost & Sullivan provides:
• Detailed insights into recent developments and trends
• Drivers, restraints, challenges, and strategic recommendations
• Analyst insights on ‘hot topics’ and emerging applications
in the market
• Market sizing and competitive analysis
• Market forecasts and opportunity analysis
• Quarterly assessments
• End user analysis within each report
© Copyright 2002 Frost & Sullivan. All Rights Reserved.
What We Offer
• Coverage: The United States
• Proven methodology encompassing extensive primary and
secondary data and research
• Focused information and strategies that cover business and
technology issues
• Credible data and analysis highlighting industry dynamics
• Winning strategies to help you create precise business plans
© Copyright 2002 Frost & Sullivan. All Rights Reserved.
Who Will Benefit?
Current Market Participants
• Find out how you compare to the competition
• Assess current and future drivers and restraints
• Determine and exploit new market share opportunities
New Entrants
• Analyze challenges associated with the industry
• Calculate time scales for strategy implementation
• Position yourself to capitalize on the market’s unmet needs
Investment Community
• Analyze long-term strategies of companies
• Determine which participants will outperform the competition
• Assess attractiveness of investing in the market
© Copyright 2002 Frost & Sullivan. All Rights Reserved.
Key Market Participants
3M Drug Delivery Systems
Abbott Laboratories
(Ross products division)
Acrux Ltd.
Adaptive Aerosol Delivery Systems/
Profile Therapeutics Ltd.
Aerogen, Inc.
Aeropharm Technology, Inc.
Alkermes, Inc.
Aradigm Corp.
AstraZeneca Pharmaceuticals LP
Aventis Pharmaceuticals, Inc.
Battelle Medical Products
Bespak Plc - Drug Delivery Technologies
BioSante Pharmaceuticals, Inc.
Boehringer Ingelheim
Pharmaceuticals, Inc.
Chiesi Farmaceutici SpA
Chiron Corp.
Direct-Haler A/S
Elan Corp., Plc - Drug Delivery
Systems
Eli Lilly and Co.
Emisphere Technologies, Inc.
Enzon, Inc.
Exhale Therapeutics, Inc.
FDA/Center for Drug Evaluation &
Research (HFD–7)
First Principals, Inc.
© Copyright 2002 Frost & Sullivan. All Rights Reserved.
Key Market Participants
Generex Biotechnology Corp.
GlaxoSmithKline, Inc.
Inhale Therapeutic Systems, Inc.
LTS LOHMANN Therapie-Systeme AG
MicroDose Technologies, Inc.
Muro Pharmaceutical, Inc.
Nobex Corp.
Novo Nordisk A/S
Oriel Therapeutics, Inc.
Ortho McNeil Pharmaceutical, Inc.
Pfizer, Inc.
Pharmacia Corp.
Profile Therapeutics Plc
Respirics, Inc.
Schering Plough Corp.
Sepracor, Inc.
Sheffield Pharmaceuticals, Inc.
SkyePharma Plc
Unimed Pharmaceuticals, Inc./
Solvay Pharmaceuticals, Inc.
Vectura Delivery Devices Ltd.
Viasys Healthcare, Inc.
ViroPharma, Inc.
© Copyright 2002 Frost & Sullivan. All Rights Reserved.
For More Information
• Call toll free 877 GO FROST
(877.463.7876)
• Fax toll free 888.690.3329
• E-mail [email protected]
• Visit www.frost.com
© Copyright 2002 Frost & Sullivan. All Rights Reserved.